Key result
Higher LVEDDI is linked to ~35% greater risk of major events in nonischemic cardiomyopathy.
Why the study?
Although myocardial fibrosis and microvascular dysfunction in DCM are associated with LV remodeling and poor outcome, these characteristics concerning HNDC remain unclear.
Does the dilated cardiomyopathy (DCM) phenotype and higher LVEDDI predict worse clinical outcomes and microvascular dysfunction compared to hypokinetic non-dilated cardiomyopathy (HNDC) in patients with nonischemic cardiomyopathy?
Cohort (n=100)
No
Does the dilated cardiomyopathy (DCM) phenotype and higher LVEDDI predict worse clinical outcomes and microvascular dysfunction compared to hypokinetic non-dilated cardiomyopathy (HNDC) in patients with nonischemic cardiomyopathy?
In patients with nonischemic cardiomyopathy, left ventricular dilatation (DCM phenotype) is an independent predictor of adverse clinical events and is associated with worse coronary microvascular dysfunction compared to hypokinetic non-dilated cardiomyopathy (HNDC).
Hypokinetic non-dilated cardiomyopathy (HNDC), a preclinical state of dilated cardiomyopathy (DCM), is characterized by left ventricular (LV) dysfunction without LV dilatation. Although myocardial fibrosis and microvascular dysfunction in DCM are associated with LV remodeling and poor outcome, these characteristics concerning HNDC remain unclear. We compared DCM and HNDC with regard to their clinical characteristics and prognosis.We retrospectively enrolled 100 patients with DCM (n = 64) or HNDC (n = 36) who underwent cardiac magnetic resonance (CMR). DCM and HNDC were classified based on an LV end-diastolic diameter index (LVEDDI). The association of LVEDDI with the composite outcome of all-cause mortality, heart failure hospitalization, or ventricular arrhythmia occurrence was assessed. Phase-contrast cine imaging was performed in a subset of 17 patients (12 with DCM and 5 with HNDC) and 7 control subjects to assess coronary flow reserve (CFR).During the follow-up period (median: 22.0 months; interquartile range: 9.0-33.8 months), patients with DCM showed higher risk of the primary outcome than those with HNDC (P = 0.026). A higher LVEDDI was significantly associated with clinical outcomes even after adjusting for covariates (i.e., brain natriuretic peptide, the presence of late gadolinium enhancement, and LV ejection fraction; adjusted hazard ratio, 1.350; 95% confidence interval, 1.008-1.808; P = 0.044). CFR in HNDC was significantly higher than that in DCM (P < 0.05) and comparable to that in the control group.LV dilatation is an independent predictor of adverse events in DCM and HNDC.
No takes yet. Share an insight, caveat, or question.
Kosuge et al. (2025) conducted a cohort in Nonischemic cardiomyopathy (Dilated cardiomyopathy and Hypokinetic non-dilated cardiomyopathy) (n=100). Higher left ventricular end-diastolic diameter index (LVEDDI) was evaluated on Composite of all-cause mortality, hospitalization for heart failure, and occurrence of ventricular arrhythmia (adjusted HR 1.350, 95% CI 1.008-1.808, p=0.044). A higher left ventricular end-diastolic diameter index was independently associated with an increased risk of adverse clinical outcomes in patients with nonischemic cardiomyopathy (adjusted HR 1.350).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: